Making life-science innovations approvable, accessible, and scalable across the EU and GCC through evidence-driven strategy and execution.
Our company
Onyx BioPartners supports life-sciences innovators across Europe and the GCC, from pharma and medtech to diagnostics, supplements, and digital health.
We structure evidence strategies, optimize development and regulatory routes, orchestrate market entry, and design adoption frameworks where scientific rigor meets commercial pragmatism.
Every decision backed by scientific, regulatory, and commercial rigor.
EMA, FDA and GCC regulatory pathways under one roof.
We build alongside you, from plan to approval to launch.
What we do
Six integrated practices. One strategic team. Engage us end-to-end or for any single stage of your journey.
From early pre-clinical development to evidence-backed supplement to R&D, we structure your development roadmap with clarity and precision.
We stage clinical programs that move efficiently from protocol to execution, integrating strategy, operations, and risk mitigation.
Approval is not paperwork. It is positioning. We develop complete evidence packages for EU, GCC, and global submissions.
Strong science must be communicated with authority. We support medical strategy, scientific messaging, and KOL engagement.
Innovation only succeeds when it is adopted. We define market access strategy, pricing, and reimbursement positioning.
Growth requires financial intelligence. We support capital readiness, financial structuring, and funding strategy alignment.
Our clients
We support life sciences companies preparing for approval, launch, market entry, and strategic expansion.
Let's talk
Book a call or send us a note. We respond to every inquiry within two business days.